Hyderabad based Contract Research and Development Organization (CRDO) Aragen Life Sciences (formerly, GVK BIO) has announced that it has been chosen by Skyhawk Therapeutics, a leader in the development of smaller molecule therapeutics that right RNA expression, as its companion in India. Through this collaboration, Aragen will provide Skyhawk with different discovery chemistry and biology service options.
This partnership is focused on accelerating Skyhawk’s study pipeline. “We are delighted to have been selected by Skyhawk Therapeutics as its partner in India. At Aragen, we believe that in every molecule there is the possibility for better health. It is with this spirit that we look forward to leveraging Aragen’s 20 years of discovery research expertise to help Skyhawk advance the development of its novel small molecule therapeutics targeting some of the world’s most intractable diseases,” stated Manni Kantipudi, CEO of Aragen.
Aragen Life Sciences Pvt Ltd (Aragen) is a worldwide leader in giving discovery, development and manufacturing options for life sciences firms. With a group of more than 3100 experts, and by means of a network of websites about the world, it delivers a seamless, integrated platform to advance client applications from discovery by means of commercialization for each smaller molecules and biologics. Established in 2001, Aragen now serves more than 450 clients worldwide across many modalities and therapeutic places.